In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .
Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: A multicenter, randomized, double-blind study
Abstract Introduction . The main objective was to compare the mean change in augmentation index of hypertensive patients treated with nebivolol or atenolol . Methods . Multicenter , double-blind r and omized study conducted in six Spanish centers . We enrolled out patients between the ages of 40 and 65 years with mild or moderate essential hypertension ( systolic blood pressure , SBP ≥ 140 mmHg to ≤ 179 mmHg and diastolic blood pressure , DBP ≥ 90 mmHg to ≤ 109 mmHg after a 2-week run-in placebo period ) . Patients received nebivolol 5 mg or atenolol 50 mg once daily . At week 3 , atenolol could be titrated up to 100 mg qd for non-responders . Additionally , patients not achieving normal blood pressure after 6 weeks could be treated with 25 mg hydrochlorothiazide . Follow-up visits were at 3 , 6 and 10 weeks . Results . The final study population of 138 patients ( 58 % men ; median age 52.6 years , range 40–67 years ) was r and omized into two groups of 69 patients each . Baseline characteristics of the two groups were similar . At the screening visit , 69 % presented with mild hypertension . Nebivolol  modified the mean augmentation index to a lesser extent than atenolol after 10 weeks ( mean difference 3.1 % , 95 % CI 0.55–5.69 ; p = 0.027 ) . A higher proportion of patients in the atenolol group required a diuretic . Reductions in central aortic pressure and peripheral arterial pressure were similar for both treatment groups . Conclusions . The study confirms that nebivolol produces a less pronounced impact on augmentation index  than atenolol
In conclusion , NVBBs , but not VBBs , determine a lower reduction in cSBP than in pSBP .
However , the difference in treatment-induced SBP amplification changes between NVBB and VBB is nearly abolished after accounting for differences in heart rate changes
β-Blockers are less effective than other antihypertensive drug classes in reducing central systolic blood pressure ( cSBP ) as compared with peripheral SBP ( pSBP ) .
Whether this effect is less pronounced with vasodilating β-blockers ( VBB ) when compared with nonvasodilating β-blockers ( NVBB ) remains unsettled .